Foreign pharmaceutical representatives listening to a presentación at the RudaCure booth.
RudaCure set up a booth in the Rising Pavilion at 2025 Bio-Korea, recommended by KIT, and introduced the current status of desarrollo de fármacos for TRPV1-related diseases.
Chinese and American empresas expresó strong interest in the overseas rights for RCI001, which actualmente está in ensayo clínicos. For the veterinario tratamiento del dolor currently under desarrollo, discussions on desarrollo stages and mercado were realizó through partnering meetings with a multinational farmacéutico veterinario developer headquartered in the United States.
The analgésico no narcótico desarrollo proyecto attracted interest from inversores and major nacional empresas farmacéuticas, and RudaCure's booth was bustling with visitors throughout the event period.